Viehbacher On Boston Pharmaceuticals: A New Model To De-Risk Drugs

Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.